Literature DB >> 12527213

Recognition of pathogen-associated molecular patterns by TLR family.

Shizuo Akira1, Hiroaki Hemmi.   

Abstract

Toll-like receptors (TLRs) are type I transmembrane proteins involved in innate immunity by recognizing microbial conserved structures. Recent studies have shown that TLR3 recognizes dsRNA, a viral product, whereas TLR9 recognizes unmethylated CpG motifs frequently found in the genome of bacteria and viruses, but not vertebrates. TLR7 recognizes small synthetic immune modifiers including imiquimod, R-848, loxoribine, and bropirimine, all of which are already applied or promising for clinical use against viral infections and cancers. Plasmacytoid dendritic cells express TLR7 and TLR9, and respond to TLR7 and TLR9 ligands by producing a large amount of interferon (IFN-alpha). These results indicate that TLR3, TLR7 and TLR9 may play an important role in detecting and combating viral infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527213     DOI: 10.1016/s0165-2478(02)00228-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  331 in total

1.  Bacterial DNA induces pulmonary damage via TLR-9 through cross-talk with neutrophils.

Authors:  Kiyoshi Itagaki; Yasaman Adibnia; Shiqin Sun; Cong Zhao; Tolga Sursal; Yu Chen; Wolfgang Junger; Carl J Hauser
Journal:  Shock       Date:  2011-12       Impact factor: 3.454

2.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

3.  Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Authors:  Thanh Nhan Nguyen Pham; Cheol Yi Hong; Jung-Joon Min; Joon-Haeng Rhee; Truc Anh Thi Nguyen; Byoung Chul Park; Deok-Hwan Yang; Young-Kyu Park; Hyeong-Rok Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Exp Mol Med       Date:  2010-06-30       Impact factor: 8.718

4.  A "Toll" for Th17 cell expansion.

Authors:  Eduardo Davila; Jay Kolls
Journal:  J Leukoc Biol       Date:  2010-07       Impact factor: 4.962

5.  Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  John A West; Sean M Gregory; Vijay Sivaraman; Lishan Su; Blossom Damania
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

6.  Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury.

Authors:  Gail A Cresci; Bryan Glueck; Megan R McMullen; Wei Xin; Daniella Allende; Laura E Nagy
Journal:  J Gastroenterol Hepatol       Date:  2017-09       Impact factor: 4.029

7.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

8.  In vitro analysis of MyD88-mediated cellular immune response to West Nile virus mutant strain infection.

Authors:  Guorui Xie; Melissa C Whiteman; Jason A Wicker; Alan D T Barrett; Tian Wang
Journal:  J Vis Exp       Date:  2014-11-27       Impact factor: 1.355

9.  Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2.

Authors:  Paula Barrionuevo; Juliana Cassataro; M Victoria Delpino; Astrid Zwerdling; Karina A Pasquevich; Clara García Samartino; Jorge C Wallach; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

10.  DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells.

Authors:  Johanna Tuomela; Jouko Sandholm; Mika Kaakinen; Ankita Patel; Joonas H Kauppila; Joanna Ilvesaro; Dongquan Chen; Kevin W Harris; David Graves; Katri S Selander
Journal:  Breast Cancer Res Treat       Date:  2013-11-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.